April 20, 2026 9:05–9:23 AM
Broadway 3
Nemea Therapeutics is a preclinical-stage company developing oral small molecule inhibitors targeting mitochondrial RNA polymerase (POLRMT) for the treatment of mitochondria-dependent solid tumors.
